Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma.

Author:
  • Eva Brun
  • Elisabeth Kjellén
  • Jan Tennvall
  • Tomas G Ohlsson
  • Anders Sandell
  • Roland Perfekt
  • Johan Wennerberg
  • Sven-Erik Strand
Publishing year: 2002
Language: English
Pages: 127-135
Publication/Series: Head and Neck
Volume: 24
Issue: 2
Document type: Journal article
Publisher: John Wiley & Sons

Abstract english

BACKGROUND: Positron emission tomography (PET) provides metabolic information of tissues in vivo. The purpose of this study was to assess the value of PET with 2-[(18) F] fluoro-2-deoxy-D-glucose (FDG) in prediction of therapy outcome (tumor response, survival, and locoregional control) in locally advanced HNSCC. METHODS: Between 1993 and 1999 47 patients underwent PET before (PET(1)) and after (PET(2)) 1 to 3 weeks of radical treatment with evaluation of metabolic rate (MR) and standardized uptake value (SUV) of FDG. All patients received radiotherapy, and 10 also received neoadjuvant chemotherapy. Median follow-up time was 3.3 years. RESULTS: Low and high MR FDG at PET(2), with median value as cutoff, was associated with complete remission in 96% and 62% (p =.007), with 5-year overall survival in 72% and 35% (p =.0042) and with local control in 96% and 55% (p =.002), respectively. CONCLUSIONS: FDG PET in the early phase of treatment of HNSCC is associated with tumor response, survival, and local control. Copyright 2002 John Wiley & Sons, Inc.

Keywords

  • Cancer and Oncology
  • Otorhinolaryngology
  • Radiology, Nuclear Medicine and Medical Imaging
  • Fludeoxyglucose F 18/*diagnostic use/pharmacokinetics
  • Female
  • Head and Neck Neoplasms/mortality/*radionuclide imaging/*therapy
  • Human
  • Male
  • Middle Age
  • Predictive Value of Tests
  • Reproducibility of Results
  • Radiopharmaceuticals/*diagnostic use/pharmacokinetics
  • Squamous Cell/mortality/*radionuclide imaging/*therapy
  • Carcinoma
  • 80 and over
  • Aged

Other

Published
  • ISSN: 1043-3074
Sven-Erik Strand
E-mail: sven-erik.strand [at] med.lu.se

Project manager

Systemic Radiation Therapy Group

32

Professor emeritus

Medical Radiation Physics, Lund

32